Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00CZT
|
||||
| Former ID |
DNCL002000
|
||||
| Drug Name |
Solanezumab
|
||||
| Drug Type |
Monoclonal antibody
|
||||
| Indication | Alzheimer disease [ICD9: 331; ICD10:G30] | Phase 3 | [1], [2] | ||
| Company |
Eli Lilly
|
||||
| CAS Number |
CAS 955085-14-0
|
||||
| Target and Pathway | |||||
| Target(s) | Amyloid beta A4 protein | Target Info | Modulator | [3] | |
| KEGG Pathway | Notch signaling pathway | ||||
| Alzheimer's disease | |||||
| Reactome | Nuclear signaling by ERBB4 | ||||
| Degradation of the extracellular matrix | |||||
| Regulated proteolysis of p75NTR | |||||
| NRIF signals cell death from the nucleus | |||||
| Activated NOTCH1 Transmits Signal to the Nucleus | |||||
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | |||||
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | |||||
| EPH-ephrin mediated repulsion of cells | |||||
| WikiPathways | Notch Signaling Pathway | ||||
| Signaling by ERBB4 | |||||
| Signaling by NOTCH3 | |||||
| Signaling by NOTCH4 | |||||
| Signaling by NOTCH1 | |||||
| Signaling by NOTCH2 | |||||
| Notch Signaling Pathway | |||||
| Alzheimers Disease | |||||
| Signalling by NGF | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01900665) Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo. U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6932). | ||||
| REF 3 | Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):311-21. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.